John P. Leonard, MD
regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) reduced the risk of disease progression or death by 54% versus rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).
Results from the phase III AUGMENT trial presented at the 2018 ASH Annual Meeting showed that at a median follow-up of 28.3 months, the median progression-free survival (PFS) per independent review was 39.4 months (95% CI, 22.9–not evaluable) with R2
versus 14.1 months (95% CI, 11.4-16.7) with rituximab alone (HR, 0.46; 95% CI, 0.34-0.62; P
By investigator assessment, the median PFS was 25.3 months (95% CI, 21.2–not evaluable) versus 14.3 months (95% CI, 12.4-17.7), respectively (HR, 0.51; 95% CI, 0.38-0.69; P
Overall response rate (ORR) was also significantly improved with the combination. The ORR per independent review was 78% with R2
versus 53% with rituximab alone (P
<.0001). The 78% ORR rate in the R2
arm comprised a 44% complete response rate and a 34% partial response rate.
“AUGMENT met its primary endpoint, as R2
demonstrated statistically significant and clinically relevant superiority over rituximab/placebo for the primary endpoint of PFS,” said lead study author John Leonard, MD, associate dean for Clinical Research and Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine and New York-Presbyterian Hospital. “R2
represents an important new treatment option in patients with previously treated indolent NHL.”
The double-blind, phase III AUGMENT trial included 358 patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma (MZL) in need of treatment. Across the study, 295 patients had follicular lymphoma and 63 patients had MZL. Patient had to have received at least 1 prior chemotherapy, immunotherapy, or chemoimmunotherapy regimen, and could not be rituximab refractory.
Patients were randomized to rituximab at 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 through 5, plus either 20 mg of lenalidomide/daily on days 1 through 21 every 28 days for up to 12 cycles (n = 178) or placebo (n = 180).
Patient characteristics at baseline were well balanced overall between the 2 arms. About 60% of patients were aged ≥60 years. Over 70% of patients had advanced-stage disease at study entry. About 50% of patients had high tumor burden per the GELF criteria. Around 83% of patients in each arm had follicular lymphoma, with the remaining 17% having MZL.
The FLIPI scores in the R2
arm were low at 29%, intermediate at 31%, and high at 39%. The respective rates were 37%, 32%, and 30% in the placebo arm.
In the R2
arm, 57% of patients had received 1 prior systemic regimen, 17% had received 2, and 25% had received ≥3. In the control arm, the corresponding rates were 54%, 23%, and 23%, respectively. Eighty-five percent of patients in the R2
arm and 83% of patients in the placebo arm had prior rituximab. About 75% of patients in each arm had received a prior rituximab-containing chemotherapy regimen. Thirty-seven percent of patients in the R2
arm and 42% of patients in the placebo arm had progressed within 2 years of their last regimen.
The PFS benefit with R2
was sustained across almost all prespecified subgroups, regardless of age, disease histology, whether or not they had prior rituximab, number of prior regimens, time since last antilymphoma therapy, geographic region where treatment was received, chemoresistance status, or tumor burden status.
Leonard noted, however, that the one exception in which the PFS advantage in a subgroup was not consistent with the overall population was the subgroup of patients with MZL. In this group, the HR for PFS was 1.00 (95% CI, 0.47-2.13). “This relates to the fact that there were roughly 30 patients in each arm with MZL, which limits these comparisons,” said Leonard.
Overall survival (OS) data across the entire population showed that at a median follow-up of 28.3 months, the HR for OS was 0.61 (95% CI, 0.33-1.13). The 2-year OS rate was 93% (95% CI, 87-96) for R2
and 87% (95% CI, 81-92) for rituximab alone.
In a prespecified subgroup analysis of patients with follicular lymphoma, at a median follow-up of 28.3 months, the HR for OS was 0.45 (95% CI, 0.22-0.91; P
= .02). The 2-year OS rate was 95% (95% CI, 90-98) for R2
and 86% (95% CI, 79-91) for rituximab alone.
Thirty percent of patients in the R2
arm discontinued treatment early compared with 39% of patients in the placebo arm. The primary cause of discontinuation was disease progression, at 12% in the R2
arm versus 30% in the control arm. Adverse events (AEs) led to discontinuation in 8% of the R2 group versus 4% of the placebo group. Among patients receiving lenalidomide, 66% had at least 1 AE-related dose interruption.
“The main grade 3/4 AE difference [between the 2 arms] in adverse events [was] in neutropenia.” However, the neutropenia generally did not result in febrile neutropenia, with only 3% of patients in the R2
arm having febrile neutropenia.
Also of note, 6 patients in the R2
arm and 10 patients in the placebo arm had secondary malignancies. “Venous and arterial thromboembolic AEs were relatively low and similar in both arms,” said Leonard.
In a discussion after his presentation, Leonard was asked where he sees the R2
regimen fitting into the treatment landscape for relapsed/recurrent follicular lymphoma, given that there are several agents already approved in this setting.
“Obviously, there are other agents approved for relapsed/recurrent follicular lymphoma in different settings. There is a meaningful percentage of patients that are currently treated with single-agent rituximab. These data suggest that many of those patients, instead, could benefit from the combination of R2
,” said Leonard.
“How this compares with chemotherapy, as well as other approaches, such as PI3-kinase inhibitors, really depends on the individual situation of the patient,” added Leonard.
Leonard JP, Trněný M, Izutsu K, et al. AUGMENT: a phase III randomized study of lenalidomide plus rituximab (R2) vs rituximab/placebo in patients with relapsed/refractory Indolent non-Hodgkin lymphoma. Presented at: ASH Annual Meeting and Exposition; December 4-8, 2018; San Diego, California. Abstract 445.
<<< 2018 ASH Annual Meeting